BC Pulmonary Pulmonary Hypertension

About PH in British Columbia
PH News in Canada
PH Events in Canada
PH Services in canada
Find a PH Doctor
Play our audio PSA and our television PSA
PH Mission in British Columbia
Check out our magazine
become a part of BCPHS and help us fight to win
contact BCPHS
support our cause
memorial Donations
back to main page
 

 

British Columbia Pulmonary Hypertension Society

Serving British Columbia and the Northwest Territories

PULMONARY ARTERIAL HYPERTENSION

Pulmonary Arterial Hypertension (PAH)/ Pulmonary Hypertension (PH) is having high blood pressure in the arteries of the lungs

- Unrecognized disease of the lungs
- Serious lung disease that can be life threatening
- Can have devastating affects if left untreated
- Known as the “other high blood pressure” 
- Simple name, complex health problem
- As of yet incurable
- Treatment options are available
- PH knows no boundaries it affects people of all ages and ethnic backgrounds
- An estimated 2000-10,000 have PAH in Canada

Science of Pulmonary Arterial Hypertension/Pulmonary Hypertension

What happens to pulmonary arteries to cause PH?

- Spasm
- Infection/Inflammation
- Clots
- Genetic Abnormalities
- Scarring

Mediators/Chemical involved

- Nitric Oxide
- Prostacyclin
- Endothelin
- Thromboxane
- Serotonin
- VIP
- VEGF

Quick Facts

- People with PAH often do not look sick; an invisible health problem
- Raising awareness about Pulmonary Arterial Hypertension SAVES LIVES
- An unrecognized and misdiagnosed illness
- Average person waits 3 years to be diagnosed
- PAH has several early symptoms similar to other diseases, such as asthma.
- Most cases are detected by echocardiogram and right heart catheterization
- Takes a series of tests to get final diagnosis – diagnosis through exclusion
- PAH research is rapidly advancing
- Doctors better understand the causes and mechanisms of PAH
- A PAH gene has been identified
- Gene/stem cell research currently going on in Toronto Canada
- Human trials started in Toronto, Canada  December 2006
- This trial looks very promising – we believe a cure is possible
- Research advances will increase life span and quality of life
- Research will help reduce the cost of treating PAH
- Devastating impact on families
- Known as the silent killer
- Often affects mostly women in their child bearing years, mean age is 36
- Good days and bad days - Can make the simplest tasks of daily living difficult
- 30% of patients do not survive beyond 4 years following diagnosis, even with current reatments
- Until recently 50% of patients died 2 years after being diagnosed
- Today 50% of patients survive 5 years or longer
- At 2000 PHA international PH conference “long-term club” was redefined to mean 10 or more years survival
- Many approaching or passed 20 years since definite diagnosis
- Only cure is lung (double/single) transplant
- Lead to death if left untreated – right sided heart failure will eventually occur
- Fundraising is important to those with PAH
- find new treatment options ~to give longer and better life for patients
- so very important to support the expanding public and private research

Signs & Symptoms

A combination of the following:
- Persistent unexplained shortness of breath (especially when climbing stairs)
- Fatigue
- Swelling of the ankles and legs
- Dizziness upon standing up too fast or climbing stairs
- Chest pain
- Fainting
- Dizzy spells
- Intolerance to exercise

Epidemiology in Canada   
Condition  
Incidence/yr     
Prevalence
Idiopathic (pph)    
60
500
Scleroderma Spectrum
90
1200
HIV
~20 
400
Cirrhosis 
~120   
4000
Thromboembolism
~120
500
Congenital Heart Disease
20     
600


Treating Pulmonary Hypertension

Goals:
- Lower Pulmonary Artery pressure (PAP)
- Prolong survival
- Improve quality of life
- Reduce symptoms
- Improve ability to be active/exercise
- Provide opportunity to participate in life
- Minimize side effects
- Avoid bankrupting the patient

Treatments:
- Flolan (epoprostenol)
- Remoduli (treprostinil)**
- Tracleer (bosentan)**
- Revatio (Viagra/Sildenafil Citrate)
- Calcium Channel Blockers (CCB’s)
- Warfarin (coumadin)
- Lasix (diuretics)
- Thelin
- Digoxin
- Oxygen

In trials
- Sitaxsentan (Thelin)
- Tadalafil (Cialis)
- Ambrisentan
- Beraprost sodium
- Nitric Oxide – trials with PPHN infants, 
- Iloprost (Ventavis) basically inhaled Flolan 

Combination therapy being used now:
- Epoprostenol with bosentan and/or sildenafil**
- Remodulin with bosentan and/or sildenafil**
- Bosentan with sildenalfil**

**very costly anywhere from $5,000 to over $100,000 a year for approved PAH treatments

- very important for patient to see Pulmonary Hypertension specialist
- Only 2 adult PH specialists in BC
- Only 1 children PH specialist in BC
- Vancouver PH Clinic treats adults with PAH from all over BC
- All PAH children go to Children’s Hospital in Vancouver BC

 


Copyright Bcphs 2005 - 2007 All Rights Reserved